GEORGIAMUNE

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.

#SimilarOrganizations #People #Financial #More

GEORGIAMUNE

Industry:
Biotechnology Health Care Therapeutics

Founded:
2014-01-01

Address:
Gaithersburg, Maryland, United States

Country:
United States

Status:
Active

Total Funding:
0


Similar Organizations

ablexis-logo

Ablexis

Ablexis is a biotechnology company developing an innovative, next-generation platform for antibody drug discovery.

alethia-biotherapeutics-logo

Alethia BioTherapeutics

Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.

applied-immune-technologies-logo

Applied Immune Technologies

Applied Immune Technologies is focused on developing therapeutic molecules for cancer, viral, and autoimmune diseases. 

argenx-logo

argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

asylia-diagnostics-logo

Asylia Diagnostics

Asylia Diagnostics - precision medicine data platform for immunotherapies

bt-biotech-logo

BT Biotech

BT Bio is a start-up biotech company that will develop and sell over-the-counter tests for sexually transmitted diseases.

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

concortis-biosystems-logo

Concortis BioSystems

Concortis is a biotechnology company creating next generation biotherapeutics using their proprietary conjugation technologies and novel

crisp-hr-therapeutics-logo

CRISP-HR Therapeutics

CRISP-HR a therapeutics company has developed a proprietary, next-generation CRISPR platform to create novel therapeutics for rare diseases.

glycosyn-logo

Glycosyn

Glycosyn is a biotechnology company developing products, based on molecules.

not_available_image

Hadron Systems

Hadron Systems is a biotechnology company developing techniques and devices that support slow neutron therapy for cancers.

hawkeye-bio-logo

Hawkeye Bio

Hawkeye Bio is a medical technology company focused on the early detection of cancer, infectious disease and autoimmune disease.

igxbio-logo

IGXBio

IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.

juventas-therapeutics-logo

Juventas Therapeutics

Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.

notogen-logo

Notogen

Notogen is a biotechnology company creating regenerative therapeutics for spine, orthopedic and sports medicine related conditions.

pharmalegacy-laboratories-shanghai-co-ltd-logo

PharmaLegacy Laboratories (Shanghai) Co., Ltd.

PharmaLegacy Laboratories (Shanghai) Co., Ltd. is a provider of specialty pharmacology services in inflammation and auto-immune diseases.

proneurotech-logo

ProNeurotech

ProNeurotech is a developer of neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease.

raqia-therapeutics-logo

Raqia Therapeutics

Raqia Therapeutics is a biotechnology company developing on a revolutionary immunotherapy technique called chimeric antigen receptors.

snap-bio-logo

Snap Bio

Snap Bio is a pre-clinical start-up company focused on developing next generation therapeutics through a pioneering approach and platform.

transave-logo

Transave

Transave is a biotechnology company developing inhaled pharmaceuticals for the treatment of lung diseases.

vigil-neuroscience-logo

Vigil Neuroscience

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

waypoint-bio-logo

Waypoint Bio

Waypoint Bio is a biotechnology company developing therapeutic treatments for rare genetic diseases

Current Employees Featured

not_available_image

Samir N. Khleif
Samir N. Khleif Founder and CEO @ Georgiamune
Founder and CEO

Founder


not_available_image

Samir N. Khleif

Investors List

lauder-partners_image

Lauder Partners

Lauder Partners investment in Venture Round - Georgiamune

More informations about "Georgiamune"

Team - Georgiamune

Prior to joining Georgiamune in October 2024, Mr. Avagliano was the Chief Business Officer of G1 Therapeutics, a commercial stage oncology biotech company, from 2019 through its acquisition in 2024. ... Prior to that, Mace led …See details»

Georgiamune - Crunchbase Company Profile & Funding

Organization. Georgiamune . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Georgiamune is a biotechnology company developing next-generation immunotherapeutics …See details»

Georgiamune

“It’s such a privilege to be part of Georgiamune and to be joining this world-class team and organization that is making major strides in the discovery and development of much needed …See details»

Georgiamune Inc. - LinkedIn

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the …See details»

Georgiamune - Funding, Financials, Valuation & Investors

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases. Search Crunchbase. Start Free Trial . ... How much funding …See details»

Georgiamune - Updates, News, Events, Signals & Triggers

Nov 19, 2024 Organization. Georgiamune . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. News Insight Details. Powered by …See details»

Georgiamune Appoints Biopharma Veteran Mark ... - The Manila …

Nov 19, 2024 "It's such a privilege to be part of Georgiamune and to be joining this world-class team and organization that is making major strides in the discovery and development of much …See details»

Georgiamune Company Profile 2025: Valuation, …

Georgiamune General Information Description. Developer of immunotherapies designed to focus on oncology advancements. The company uses next-generation immunotherapeutic and homeostasis for cancer and autoimmune …See details»

Georgiamune

Georgiamune continues biotech innovation streak with first autoimmune disease-focused program based on novel biology . GAITHERSBURG, MD, September 24, 2024 – Today, Georgiamune …See details»

Georgiamune Announces First Participant Dosed in First-In-Class …

Sep 24, 2024 The company has initiated three first-in-class assets in clinical trials (GIM-122, GIM-531 and GIM-407) in the past 12 months, all based on novel biology discovered by …See details»

Our Investment in Georgiamune - General Catalyst

Aug 9, 2023 We believe Georgiamune's lead candidate, GIM-122, is a first-in-class, monoclonal dual-functioning antibody with a highly differentiated mechanism of action, that has the …See details»

Georgiamune Inc. Achieves US FDA Clearance for Investigational …

Aug 9, 2023 Georgiamune was founded by Dr. Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his …See details»

WilmerHale Advises Georgiamune on $75M Series A Financing

On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug …See details»

Georgiamune

Georgiamune receives U.S. FDA clearance for GIM-531 andcontinues to enroll patients in clinical trial testing for GIM-122. GAITHERSBURG, MD, May 29, 2024 – Today, Georgiamune Inc., a …See details»

Georgiamune - Products, Competitors, Financials, Employees ...

Georgiamune is a biotechnology company focused on reprogramming immune responses to combat cancer and autoimmune diseases within the healthcare sector. ... “It’s such a privilege …See details»

Series A - Georgiamune - 2023-08-09 - Crunchbase

Aug 9, 2023 Georgiamune raised $75000000 on 2023-08-09 in Series A. Parker Institute for Cancer Immunotherapy Parker Institute for Cancer Immunotherapy coordinates cancer …See details»

Company news - Georgiamune

Aug 9, 2023 GAITHERSBURG, MD, September 24, 2024 – Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first participant has …See details»

Georgiamune - Contacts, Employees, Board Members, Advisors

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.See details»

Pipeline - Georgiamune

The Challenge: Cancers, with their genomic instability, inflammation, and tissue destruction, can evoke immune escape mechanisms that allow the progression of tumors and prevent their …See details»

linkstock.net © 2022. All rights reserved